Zobrazeno 1 - 10
of 65
pro vyhledávání: '"Guru Sonpavde"'
Autor:
Elie W. Akl, Elio Adib, Talal El‐Zarif, Toni K. Choueiri, Charlene Mantia, Rohit Jain, William Paul Skelton, Praful Ravi, Dory Freeman, David J. Kwiatkowski, Catherine Curran, Amin Nassar, Guru Sonpavde
Publikováno v:
BJUI Compass, Vol 3, Iss 2, Pp 169-172 (2022)
BJUI Compass
BJUI Compass
Enfortumab Vedotin (EV) is approved for metastatic urothelial carcinoma (mUC) progressing post-platinum and PD1/L1 inhibitor therapy. Erdafitinib is approved for post-platinum mUC with activating somatic genomic alterations (GAs) in FGFR2/3. Informat
Autor:
Aristotelis Bamias, Vadim S. Koshkin, Victor Sacristan Santos, Matthew D. Galsky, Ana Fröbe, Joseph J. Park, David J. Pinato, Pedro Isaacsson Velho, Christopher J. Hoimes, Pavlos Msaouel, Jayanshu Jain, Daniel Castellano, Leonidas Nikolaos Diamantopoulos, Benjamin A. Gartrell, Neeraj Agarwal, Abhishek Tripathi, Ali Raza Khaki, Rafael Morales-Barrera, Ajjai Alva, Stepan M. Esagian, Lucia Carril-Ajuria, Jure Murgic, Tyler F. Stewart, Sandy T. Liu, Evan Shreck, Monika Joshi, Noah M. Hahn, Pedro C. Barata, Mehmet Asim Bilen, Lucia Alonso Buznego, Marcus Marie Moses, Ivan de Kouchkovsky, Vivek Kumar, Alexandra Drakaki, Yousef Zakharia, Ariel Ann Nelson, Roubini Zakopoulou, Petros Grivas, Evan Y. Yu, Alejo Rodriguez-Vida, Ignacio Duran, Alexander Sankin, Mark P. Lythgoe, Guru Sonpavde, Rana R. McKay, Michael Edward Devitt
Publikováno v:
BJU International. 128:196-205
Objectives: To compare clinical outcomes between patients with locally advanced (unresectable) or metastatic urothelial carcinoma (aUC) in the upper and lower urinary tract receiving immune checkpoint inhibitors (ICIs). Patients and methods: We perfo
Autor:
Vadim S. Koshkin, Bernadett Szabados, Daniel Castellano, Matthew D. Galsky, Petros Grivas, Lucia Carril-Ajuria, Min Y. Teo, Daniele Raggi, Guru Sonpavde, Parissa Alerasool, Thomas Powles, Lillian Werner, Jacob Gaines, Xiao X. Wei, Ravindran Kanesvaran, Joaquim Bellmunt, Jonathan E. Rosenberg, Andrea Necchi, Noah M. Hahn, Rana R. McKay, Laura Morrison, Pedro Isaacsson Velho
Publikováno v:
J Urol
PURPOSE: Current first-line treatment options in patients with metastatic urothelial carcinoma (mUC) unfit to receive cisplatin-containing chemotherapy include PD-1/L1 inhibitors and carboplatin-containing chemotherapy. However, the optimal sequencin
Autor:
Opeyemi Jegede, Lauren C. Harshman, Guru Sonpavde, Mark Pomerantz, Mark A. Preston, Chia Jen Liu, Joaquim Bellmunt, Bradley Alexander McGregor, Amin Nassar, Jaegil Kim, Neal I. Lindeman, Atul B. Shinagare, Kent W. Mouw, Sabina Signoretti, Atish D. Choudhury, Eliezer M. Van Allen, Toni K. Choueiri, Fei Dong, David J. Kwiatkowski, Xiao X. Wei
Publikováno v:
British Journal of Cancer. 122:555-563
Background In metastatic urothelial carcinoma (mUC), predictive biomarkers that correlate with response to immune checkpoint inhibitors (ICIs) are lacking. Here, we interrogated genomic and clinical features associated with response to ICIs in mUC. M
Autor:
Juergen E. Gschwend, Nathalie Garzon, Shilpa Gupta, Bradley Raybold, Mark Rutstein, Danny Liaw, Michiel S. van der Heijden, Gary D. Steinberg, Matthew D. Galsky, Guru Sonpavde, Mohammed Ibrahim, Andrea Necchi
Publikováno v:
Future oncology (London, England). 16(2):4359-4368
Immune checkpoint inhibitors have revolutionized the treatment of patients with metastatic urothelial carcinoma. In cisplatin-eligible muscle-invasive bladder cancer (MIBC), cisplatin-based neoadjuvant chemotherapy (NAC) before radical cystectomy imp
Autor:
B. Mellado, M. Gil, M.J. Chisamore, Guru Sonpavde, Yohann Loriot, M. Shimura, Vadim S. Koshkin, G. Tomlinson, Clara Hwang
Publikováno v:
European Urology Open Science. 33:S383-S384
Autor:
I. Bin Riaz, Dory Freeman, Bradley Alexander McGregor, Y. Choudhury, Guru Sonpavde, Praful Ravi, Arvind Ravi, N. Corsaro, M. Pek, Kerry L. Kilbridge, Charlene Mantia, Catherine Curran, M-H. Tan, C-X. Pan
Publikováno v:
Annals of Oncology. 32:S717-S718
Autor:
Rakesh K. Jain, William Paul Skelton, Guru Sonpavde, Mahrukh Naqvi, Gregory R. Pond, Catherine Curran, Dory Freeman, Young-Chul Kim, Amin Nassar, Rohit Jain, Pier Vitale Nuzzo, Sarah Abou Alaiwi
Publikováno v:
Clin Genitourin Cancer
We hypothesized that concurrent angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) would improve outcomes in patients with metastatic urothelial carcinoma receiving PD1/L1 inhibitors by downregulating transformi
Autor:
Andrea Necchi, Daniel Hennessy, Juliane Manitz, Toni K. Choueiri, Noah M. Hahn, Shaad Essa Abdullah, Chen Gao, Constanze Kaiser, Ashok K. Gupta, Sandy Srinivas, Andrea B. Apolo, Jonathan E. Rosenberg, Darren Tayama, Doris Makari, Gregory R. Pond, Guru Sonpavde, Dean F. Bajorin, Matthew D. Galsky, Thomas Powles, Petros Grivas, Robert Dreicer, Guenter Niegisch
Publikováno v:
J Urol
PURPOSE: A prognostic model for overall survival of post-platinum patients with metastatic urothelial carcinoma receiving PD-1/PD-L1 inhibitors is necessary as existing models were constructed in the chemotherapy setting. MATERIALS AND METHODS: Patie
Autor:
Sai Akshaya Hodigere Balasubramanya, Sumit Agarwal, Sooryanarayana Varambally, Balabhadrapatruni V. S. K. Chakravarthi, Chong-Xian Pan, Guru Sonpavde, James E. Ferguson, Upender Manne, Alyncia D. Robinson, Gurudatta Naik, Darshan S. Chandrashekar, George J. Netto, Saroj Nepal, Hasibur Rehman, Marie-Lisa Eich
Metastatic urothelial carcinoma of the bladder is generally incurable by current systemic therapy. Molecular characterization of bladder cancer (BLCa) has revealed multiple candidate driver genes for BLCa tumorigenesis. Epigenetic/chromatin modifiers
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7b4c6f157a4d159df9d58e4d296e4318
https://doi.org/10.1101/2021.01.12.426383
https://doi.org/10.1101/2021.01.12.426383